

Title (en)
USE OF LAMELLARIN-CLASS ALKALOIDS IN METHODS OF TREATMENT

Title (de)
VERWENDUNG VON LEMELLARIN ALKALOIDEN IN THERAPEUTISCHEN VERFAHREN

Title (fr)
UTILISATION D'ALCALOIDES DE LA CLASSE LAMELLARINE DANS DES PROCEDES DE TRAITEMENT

Publication
EP 0835108 A1 19980415 (EN)

Application
EP 96922197 A 19960626

Priority
• IB 9600742 W 19960626
• US 49646595 A 19950629

Abstract (en)
[origin: US6087370A] The lamellarin compounds disclosed herein have been found to be inhibitors of MDR, i.e., acquired multidrug resistance, which has become a major problem in the treatment of various cancers. The lamellarin compounds disclosed herein have also been found to be cytotoxic to MDR cells. MDR is believed to be associated with certain alterations in tumor cells, including an over-expression of a certain high molecular weight membrane glycoprotein and a decrease in the ability of the tumor cell to accumulate and retain chemotherapeutic agents. The present invention is thus directed to methods of treating MDR-type tumors with an effective anti-MDR amount (either inhibitory or cytotoxic) of one or more lamellarin compounds, which compounds have been found to be effective antitumoral agents against MDR cells.

IPC 1-7
A61K 31/435

IPC 8 full level
C07D 491/147 (2006.01); **A61K 31/435** (2006.01); **A61K 31/437** (2006.01); **A61K 31/4433** (2006.01); **A61K 31/4745** (2006.01); **A61K 31/475** (2006.01); **A61K 31/65** (2006.01); **A61K 31/70** (2006.01); **A61K 35/56** (2015.01); **A61K 35/655** (2015.01); **A61K 38/08** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP US)
A61K 31/437 (2013.01 - EP US); **A61K 31/4745** (2013.01 - EP US); **A61K 31/475** (2013.01 - EP US); **A61K 31/70** (2013.01 - EP US); **A61P 35/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP)

C-Set (source: EP US)
1. **A61K 38/08 + A61K 31/435**
2. **A61K 31/70 + A61K 31/435**
3. **A61K 31/70 + A61K 31/435**
4. **A61K 31/475 + A61K 31/435**
5. **A61K 31/475 + A61K 2300/00**
6. **A61K 31/70 + A61K 2300/00**
7. **A61K 38/08 + A61K 2300/00**

Cited by
CN112300232A

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
US 6087370 A 20000711; AT E208196 T1 20011115; AU 6316796 A 19970130; AU 700420 B2 19990107; CA 2225807 A1 19970116; CA 2225807 C 20080422; DE 69616792 D1 20011213; DE 69616792 T2 20020620; DK 0835108 T3 20020318; EP 0835108 A1 19980415; EP 0835108 B1 20011107; ES 2164899 T3 20020301; HU 225588 B1 20070328; HU P9900186 A2 19990628; HU P9900186 A3 20010828; JP 4153992 B2 20080924; JP H11508882 A 19990803; MX 9800248 A 19981130; PL 184667 B1 20021129; PL 324282 A1 19980511; PT 835108 E 20020328; RU 2188637 C2 20020910; US 5852033 A 19981222; WO 9701336 A1 19970116

DOCDB simple family (application)
US 21640698 A 19981218; AT 96922197 T 19960626; AU 6316796 A 19960626; CA 2225807 A 19960626; DE 69616792 T 19960626; DK 96922197 T 19960626; EP 96922197 A 19960626; ES 96922197 T 19960626; HU P9900186 A 19960626; IB 9600742 W 19960626; JP 50428597 A 19960626; MX 9800248 A 19980107; PL 32428296 A 19960626; PT 96922197 T 19960626; RU 98101364 A 19960626; US 49646595 A 19950629